S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL

類似資料

• Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
  著者:: Pavel Burda, 等
  出版事項: (2024-10-01)
• Asciminib in late-line CML treatment
  著者:: Kendra Sweet, 等
  出版事項: (2025-08-01)
• S154: IMATINIB-RESISTANT CLONES ISOLATED FROM A MODEL OF BLAST CRISIS OF CHRONIC MYELOID LEUKAEMIA DIFFER IN MUTATIONS IN BCR::ABL1 AND OTHER CANCER RELATED GENES AND IN THEIR SENSITIVITY TO BH3-MIMETICS
  著者:: A. Laznicka, 等
  出版事項: (2022-06-01)
• P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
  著者:: A. Innes, 等
  出版事項: (2022-06-01)
• P209 | COMBINATION OF PONATINIB AND ASCIMINIB IN PATIENTS WITH ADVANCED CHRONIC MYELOID LEUKEMIA
  著者:: G. Cotilli, 等
  出版事項: (2025-09-01)